Author argues IMRN is a bottomed-out biotech with military/DoD backing, an imminent ProIBS launch, and a planned Phase 2 trial for IMM-200 in H1 2026.
IMRN — LONG The author claims IMRN is a bottomed-out biotech play with huge backing from the military and Department of Defense, supported by ongoing research relationships with major US military institutions. The stated catalysts are the imminent launch of ProIBS (originally scheduled for Q4) and the initiation of a Phase 2 clinical trial for IMM-200 during the first half of 2026. The author frames these events as drivers of a potential 'next big biotech runner.'
IMRN is a bottomed out biotech play with huge backing by the military and department of defense. They have ongoing research relationships with major US military institutions They are planning to launch ProIBS any day now (originally scheduled for Q4) + are initiating a phase 2 clinical trial for IMM-200 during the first half of 2026.
This Reddit post, published January 12, 2026, features u/Alpha1153 discussing IMRN. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Alpha1153 · Tickers: IMRN